Rx Importation Bills "Unlikely" To Become Law, Lilly Tells Investors
Executive Summary
The prescription drug re-importation amendments riding on House and Senate Agriculture Appropriations bills are "unlikely" to survive conference and become law, Lilly told investors July 20.
You may also be interested in...
Rx Import Bill Undercuts FDA Approach To Quality Control, Lilly Exec Testifies
FDA's process focus in GMP regulation illustrates the importance of manufacturer control over importation into the U.S., Lilly Europe/North America Area Quality Control Leader Nikki Mehringer told the House Commerce/Oversight Subcommittee Oct. 3.
Rx Import Bill Undercuts FDA Approach To Quality Control, Lilly Exec Testifies
FDA's process focus in GMP regulation illustrates the importance of manufacturer control over importation into the U.S., Lilly Europe/North America Area Quality Control Leader Nikki Mehringer told the House Commerce/Oversight Subcommittee Oct. 3.
Rx Re-Importation Bill Impact Could Be Limited By Canadian Export Laws
Canadian export regulations would limit the impact of pharmaceutical re-importation proposals pending in Congress, a former Canadian official said at a July 24 American Enterprise Institute conference in Washington, D.C.